We were intrigued by the recent publication from Kristiansen et al1 in Blood Advances, which presents findings regarding the prevalence of the JAK2V617F mutation in patients with ischemic stroke (IS). Using a case-control design with 538 IS cases and 1613 age- and sex-matched controls free of ischemic cerebrovascular disease, the study unveiled a statistically significant disparity in the occurrence of this somatic mutation
Are the available data sufficient to suggest cytoreductive agents for patients with CHIP and stroke? / Barbui, Tiziano; Carobbio, Alessandra; Vannucchi, Alessandro M.; De Stefano, Valerio. - In: BLOOD ADVANCES. - ISSN 2473-9529. - ELETTRONICO. - 7:(2023), pp. 7551-7553. [10.1182/bloodadvances.2023012007]
Are the available data sufficient to suggest cytoreductive agents for patients with CHIP and stroke?
Vannucchi, Alessandro M.;
2023
Abstract
We were intrigued by the recent publication from Kristiansen et al1 in Blood Advances, which presents findings regarding the prevalence of the JAK2V617F mutation in patients with ischemic stroke (IS). Using a case-control design with 538 IS cases and 1613 age- and sex-matched controls free of ischemic cerebrovascular disease, the study unveiled a statistically significant disparity in the occurrence of this somatic mutation
| File | Dimensione | Formato | |
|---|---|---|---|
|
art 3 pg 1.pdf
accesso aperto
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Creative commons
Dimensione
388.65 kB
Formato
Adobe PDF
|
388.65 kB | Adobe PDF |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
